Cancer Market

An Unmet Clinical Need

Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both external factors (tobacco, chemicals, radiation, infectious organisms, etc.) and internal factors (inherited mutations, hormones, immune conditions and mutations that occur from metabolism).

Cancer claims the lives of over six million people worldwide each year. The American Cancer Society estimates that more than 12 million new cases of cancer are diagnosed each year worldwide. While progress has been made in early diagnoses and treatment, most conventional therapies — including surgery, radiation and chemotherapy – can include a host of unwanted side effects that can dramatically affect a patient’s quality of life after treatment, whether the treatment is successful or not.

Our goal is to provide an effective cancer treatment modality that does not result in the unwanted side effects that are common with currently available therapies.

The Prostate Cancer Opportunity

In the United States, prostate cancer is the most frequently diagnosed form of cancer in men – over 240,000 new cases were diagnosed in 2011 on top of 2 million existing cases — and the second leading cancer related cause of death.  It is estimated that nearly 17% of men will receive a prostate cancer diagnosis in their lifetime and that over $8 billion is spent annually to treat prostate cancer.

There is a significant shift taking place in the diagnosis and treatment of early stage prostate cancer. This is due to increasing resistance by governments, insurance companies and the clinical community to the aggressive diagnosis of prostate cancer with PSA testing and the subsequent over treatment of men. The current diagnostic and treatment paradigm is costly and leaves men with significant and debilitating side-effects including sexual and urinary dysfunction. Most of the prostate cancers diagnosed early will not prove to be a clinical problem in a man’s lifetime if left untreated. Yet early treatment of these cancers would help to prevent advanced, deadly cancer in the small fraction of these cancers that are aggressive and often lead to the later stage mortality that takes the lives of approximately 35,000 men in the U.S. each year (estimated 300,000 worldwide).

If a lower cost treatment that did not cause significant side effects were available, it would make the continued early diagnosis and treatment of prostate cancer much more acceptable, thus preventing thousands of cancer deaths and greatly limiting costly and harmful treatments such as radical prostatectomy and radiation. LaZure’s LDAC technology offers this opportunity and could have a major impact on the rapidly evolving prostate cancer treatment market.